SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor ongoing discussions regarding strategic mineral assets in Greenland and speculate on potential positive catalysts following recent metallurgical test results and pilot plant developments. The community remains highly focused on the company's long-term potential in the heavy rare earth sector while debating the impact of management's communications and the timing of a revised bankable feasibility study.

Maulcoin

Maulcoin is trending as a highly active community-driven memecoin project, with members rallying to maintain its visibility despite technical hurdles with ticker and chart integration. Investors are actively debating the coin's long-term sustainability while leveraging social media raids and decentralized exchange platforms to push for wider adoption.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is trending as a community-driven project on Solana, drawing attention for its long-term focus, voluntary supply locks via its "Airlock" system, and a dedicated holder base that emphasizes consistent building over short-term hype. Investors are actively highlighting the project's deep narrative roots, active treasury, and persistent community engagement as key differentiators in the broader memecoin market.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is currently trending as investors scrutinize the company's massive cash pile and potential for capital allocation strategies under new leadership following a period of underperformance. The community remains deeply divided, with some betting on a long-term defensive play while others express frustration over the stock's lack of momentum compared to broader market indices.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing intense social media debate as investors weigh a major equity distribution program against a record backlog and bullish analyst upgrades. While some community members warn of dilution and overvaluation following a recent price surge, others argue the current move is an opportunistic play by management to fund massive demand in the AI and silicon photonics sectors.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors digest the recent leadership transition in R&D and intensified pressure from top shareholder Shah Capital, who is demanding strategic overhauls and improved accountability. The community remains deeply divided, with many expressing frustration over persistent price volatility and a lack of clear communication from management regarding partnership timelines for their core vaccine assets.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as investors grapple with extreme volatility in the semiconductor sector, driven by ongoing geopolitical tensions in the Middle East and concerns over potential supply chain disruptions. The community is actively debating whether to treat recent price fluctuations as a genuine trend reversal or a temporary 'dead cat bounce,' with many traders highlighting the risks of holding leveraged ETFs amid contradictory reports regarding ceasefire agreements and chip sector valuations.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community highlights recent legal action against an AI-powered smear campaign and celebrates the companys milestone of over 100 million battery swaps. Investors are actively debating the stock's potential for a breakout, driven by anticipation for upcoming model launches and a strong sentiment that the company is currently undervalued compared to its operational growth.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense volatility as investors debate the impact of a short-selling report alleging that competitors like Anthropic are gaining enterprise market share. While some market participants dismiss the negative commentary as a coordinated manipulation tactic to suppress the stock, others remain concerned about the company's premium valuation and the long-term competitive landscape in the AI sector.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne is trending as investors focus on its critical role in the semiconductor supply chain, with the community actively discussing its massive growth potential tied to AI-driven data center demand and specialized chip testing. Market participants are heavily debating the stock's future trajectory, weighing long-term structural tailwinds in automation against concerns regarding competitive market share shifts and valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ALT @2MargaritaLunch Chop, this kind of post is EXACTLY why the $ALT board continues to remain disconnected on $ALT&#39;s reality.  Let me help: 
 
1) Statistically, drugs that received BTD have a 65-72% probability for approval compared to 50-60% for Phase 3 drugs, overall.  46% BTDs are in Oncology. 
 
2) Current 4 drugs in the MASH sector with BTD (Including $IVA, which leads in Fibrosis Improvement, and $SGMT, which shows excellent results with $MDGL). 
 
3) No MASH drug that has applied for BTD has been denied.  This is expected given the early stages of sector development and multiple (potential) MOAs. 
 
So thanks for sharing your hopium of success based on receiving BTD, but I think right-sizing those expecations for $ALT is more warranted than most, especially given they are significantly lagging behind excellent performing companies that are significantly further along than $ALT  
 
Cheers!

Jay Isaac

Spodero

@Dipwhits and what, like 75% of fda BTD molecules make it to market? Combined with the tolerability and overwhelming support of professionals in blind study preferring Pemvi over other treatments ? Thank you Linda !

StockTwits for iOS

Chop1182

StockTwits Web

Altimmune Inc

Inventiva - ADR

Sagimet Biosciences Inc

Madrigal Pharmaceuticals Inc

 Chop, this kind of post is EXACTLY why the 

 board continues to remain disconnected on 

's reality.  Let me help: 
 
1) Statistically, drugs that received BTD have a 65-72% probability for approval compared to 50-60% for Phase 3 drugs, overall.  46% BTDs are in Oncology. 
 
2) Current 4 drugs in the MASH sector with BTD (Including 

, which leads in Fibrosis Improvement, and 

). 
 
3) No MASH drug that has applied for BTD has been denied.  This is expected given the early stages of sector development and multiple (potential) MOAs. 
 
So thanks for sharing your hopium of success based on receiving BTD, but I think right-sizing those expecations for 

 is more warranted than most, especially given they are significantly lagging behind excellent performing companies that are significantly further along than 

Vanda Pharmaceuticals Inc

Sanofi-Aventis

SPDR S&P Biotech ETF

SELLAS Life Sciences Group Inc

Viking Therapeutics Inc

Milestone Pharmaceuticals Inc

Fractyl Health Inc.

The Legendary Mayor

@BioRich @2MargaritaLunch Breakthrough is a very big deal, there is no minimizing that, it and Accelerated Approval design are the two highest forms of backing and support the FDA can provide. Additionally, coming in after other molecules have been granted Breakthrough status is not a negative or means you are behind, it is actually a greater affirmation as Breakthrough Designation means you are bringing something new to the party that the molecules infront of you do not.  
 
Pemvi does not and has never had a science, data, or clinical problem, it is going to be a very lucractive drug at some point. The problem has always been the humans in charge.

Darius

 Breakthrough is a very big deal, there is no minimizing that, it and Accelerated Approval design are the two highest forms of backing and support the FDA can provide. Additionally, coming in after other molecules have been granted Breakthrough status is not a negative or means you are behind, it is actually a greater affirmation as Breakthrough Designation means you are bringing something new to the party that the molecules infront of you do not.  
 
Pemvi does not and has never had a science, data, or clinical problem, it is going to be a very lucractive drug at some point. The problem has always been the humans in charge.

Lilly(Eli) & Co

Novo Nordisk A/S

Pfizer Inc

Hims & Hers Health Inc

Medline Inc.

Britt Peterson

@Diapers_Tequila @2MargaritaLunch My point was meant to be simple.  This $ALT board preaches historical probabilities as basis for sure success.  That&#39;s obviously not the case.  Is $ALT a differentiated approach that the Agency is willing to see play out, of course.  They&#39;ve done that with the others mentioned as well.  The point there is simple BTD for $ALT is not the golden ticket many on here are pumping that it is.

 board preaches historical probabilities as basis for sure success.  That's obviously not the case.  Is 

 a differentiated approach that the Agency is willing to see play out, of course.  They've done that with the others mentioned as well.  The point there is simple BTD for 

 is not the golden ticket many on here are pumping that it is.